Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HDAC11 is a novel drug target in carcinomas

1 Oct 2012

Abstract excerpt

Inhibition of histone deacetylase (HDAC) activity as stand-alone or combination therapy represents a promising therapeutic approach in oncology. The pan- or class I HDAC inhibitors (HDACi) currently approved or in clinical studies for oncology give rise to dose-limiting toxicities, presumably because of the inhibition of several HDACs. This could potentially be overcome by selective blockade of single HDAC family...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23024001
DOI: 10.1002/ijc.27876

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HDAC11 is a novel drug target in carcinomasPMID 23024001Read ↗

HDAC11: A novel target for improved cancer therapySemantic proximity Read ↗

Targeting Histone Deacetylases: Opportunities for Cancer Treatment and ChemopreventionSemantic proximity Read ↗

Histone-Deacetylase Inhibitors for the Treatment of CancerSemantic proximity Read ↗

A pan‐cancer analysis identifies HDAC11 as an immunological and prognostic biomarkerSemantic proximity Read ↗

Unraveling HDAC11: Epigenetic orchestra in different diseases and structural insights for inhibitor designSemantic proximity Read ↗

Targeting class I histone deacetylases in cancer therapySemantic proximity Read ↗

Targeting histone deacetylases for the treatment of cancer and inflammatory diseasesSemantic proximity Read ↗

Discovery of Novel Class of Histone Deacetylase Inhibitors as Anticancer AgentsSemantic proximity Read ↗

Role of HDAC6 and Its Selective Inhibitors in Gastrointestinal CancerSemantic proximity Read ↗

Histone Deacetylases and their Inhibitors in Colorectal Cancer Therapy: Current Evidence and Future ConsiderationsSemantic proximity Read ↗

A novel class I HDAC inhibitor, MPT0G030, induces cell apoptosis and differentiation in human colorectal cancer cells via HDAC1/PKCδ and E-cadherinSemantic proximity Read ↗

Natural Compound Histone Deacetylase Inhibitors (HDACi): Synergy with Inflammatory Signaling Pathway Modulators and Clinical Applications in CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.